Subscribe to our Newsletters !!
The connection between genes and traits is one of
Our customers depend on the high performance and r
Few names in the medical history have had a profou
Alembic Pharmaceuticals Limited appoints Mr. Manis
Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and her
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of The Magazine
Bharat Biotech Place to Create intranasal COVID-19 vaccine: This is all you need to know Hyderabad-based Bharat Biotech announced on September 23 that it has collaborated with the Washington University School of Medicine to develop an intranasal COVID-19 vaccine.
Here are seven things you need to know about the novel chimp-adenovirus vaccine candidate:
Bharat Biotech plans to create up to 100 crore doses of the intranasal coronavirus vaccine.
The Hyderabad-based company will have the right to distribute the single-dose vaccine in most markets except in the United States, Japan, and Europe.
The intranasal novel coronavirus vaccine is expected to decrease dependence on needles and syringes and help overcome the potential difficulties that come with distributing a vaccine, while also negating the requirement for employees to administer the vaccine taken.
Unlike most other coronavirus vaccines being developed, this vaccine will be administered via the nose, which is often the initial site of an infection. Scientists have claimed that the nasal route for vaccination has often seen a more powerful immune response throughout the body.
Dr David Curiel, Professor of Radiation Oncology at Washington University School of Medicine has said an intranasal vaccine will”not just shield against COVID-19, but also stop the spread of this disease by offering another kind of immunity that occurs mostly in the cells that line the nose and throat.”
Though the phase-I human trials of the intranasal COVID-19 vaccine will be run at the Treatment Assessment Unit of Saint Louis University in the United States, Bharat Biotech is supposed to pursue the other stages of clinical trials in India.
This vaccine will enlarge Bharat Biotech’s vaccine portfolio because the company is already developing coronavirus vaccine COVAXIN, which is currently in the second phase of human clinical trials.
